BCYC - Bicycle Therapeutics plc
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United Kingdom
Type: Equity
BCYC price evolution
BCYC
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $890.86 | $961.36 | $457 | $526.42 |
| Short term investments | ||||
| Net receivables | $57.98 | $46.68 | $39.06 | $24.04 |
| Inventory | ||||
| Total current assets | $966.19 | $1028.26 | $515.96 | $561.87 |
| Long term investments | ||||
| Property, plant & equipment | $20.61 | $22.52 | $24.81 | $27.68 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $996.75 | $1057.36 | $547.14 | $595.34 |
| Current liabilities | ||||
| Accounts payable | $5.71 | $7.45 | $7.06 | $13.05 |
| Deferred revenue | ||||
| Short long term debt | $27.5 | $4.97 | $4.88 | |
| Total current liabilities | $56.41 | $69.61 | $49.51 | $69.54 |
| Long term debt | $8.5 | $30.8 | $30.7 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $165.71 | $183.54 | $191.1 | $224.41 |
| Shareholders' equity | ||||
| Retained earnings | -$628.94 | -$578.14 | -$538.32 | -$511.76 |
| Other shareholder equity | -$3.19 | -$1.09 | -$0.78 | -$1.3 |
| Total shareholder equity | $873.81 | $356.05 | $370.93 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $526.42 | $339.15 | $438.68 | $135.99 |
| Short term investments | ||||
| Net receivables | $24.04 | $21.21 | $11.91 | $14.63 |
| Inventory | ||||
| Total current assets | $561.87 | $369.38 | $458.56 | $155.72 |
| Long term investments | ||||
| Property, plant & equipment | $27.68 | $32.77 | $17.79 | $3.61 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $595.34 | $410.61 | $479.79 | $161.15 |
| Current liabilities | ||||
| Accounts payable | $13.05 | $6.47 | $2.72 | $1.36 |
| Deferred revenue | ||||
| Short long term debt | $4.88 | $3.12 | $2.38 | |
| Total current liabilities | $69.54 | $53.34 | $36.24 | $23.13 |
| Long term debt | $30.7 | $30.32 | $29.87 | $14.51 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $224.41 | $139.83 | $133.54 | $65.69 |
| Shareholders' equity | ||||
| Retained earnings | -$511.76 | -$331.1 | -$218.38 | -$151.56 |
| Other shareholder equity | -$1.3 | $0.39 | -$3.39 | -$3.19 |
| Total shareholder equity | $370.93 | $270.78 | $346.25 | $95.46 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.36 | $19.53 | $5.33 | |
| Cost of revenue | $38.3 | |||
| Gross Profit | -$28.94 | $19.53 | ||
| Operating activities | ||||
| Research & development | $47.37 | $34.86 | ||
| Selling, general & administrative | $17.71 | $16.38 | ||
| Total operating expenses | $56.01 | $51.25 | $59.75 | |
| Operating income | -$46.65 | -$31.72 | ||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.12 | -$0.35 | $0.32 | |
| Interest expense | -$0.82 | -$0.82 | $5.64 | |
| Net income | ||||
| Net income | -$39.81 | -$26.56 | -$49.1 | |
| Income (for common shares) | -$39.81 | -$26.56 | ||
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $26.98 | |||
| Cost of revenue | $156.5 | |||
| Gross Profit | -$129.52 | |||
| Operating activities | ||||
| Research & development | $180.96 | |||
| Selling, general & administrative | $60.43 | |||
| Total operating expenses | $216.92 | |||
| Operating income | -$189.95 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $1.46 | |||
| Interest expense | -$3.26 | |||
| Net income | ||||
| Net income | -$180.66 | |||
| Income (for common shares) | -$180.66 | |||
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$39.81 | -$26.56 | -$49.1 | |
| Operating activities | ||||
| Depreciation | $1.64 | $1.66 | $1.65 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$44.63 | -$70.87 | -$47.29 | |
| Investing activities | ||||
| Capital expenditures | -$0.42 | -$0.01 | -$0.05 | |
| Investments | ||||
| Total cash flows from investing | -$0.87 | -$0.42 | -$0.01 | -$0.05 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $549.61 | $1.87 | ||
| Net borrowings | ||||
| Total cash flows from financing | $519.55 | $549.61 | $1.87 | $0.39 |
| Effect of exchange rate | $1.09 | |||
| Change in cash and equivalents | $364.44 | $504.37 | -$69.43 | -$45.66 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$180.66 | -$112.72 | -$66.82 | -$51.01 |
| Operating activities | ||||
| Depreciation | $6.55 | $3.69 | $1.41 | $1.28 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$60.63 | -$86.11 | -$14.79 | -$17.79 |
| Investing activities | ||||
| Capital expenditures | -$18.99 | -$2.03 | -$1.2 | |
| Investments | ||||
| Total cash flows from investing | -$2.93 | -$18.99 | -$2.03 | -$1.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $250.03 | $6.69 | $305.73 | $48.42 |
| Net borrowings | $15 | $15 | ||
| Total cash flows from financing | $250.03 | $6.69 | $320.73 | $62.84 |
| Effect of exchange rate | -$1.21 | $0.02 | ||
| Change in cash and equivalents | $187.82 | -$99.53 | $302.69 | $43.87 |
News
Fundamentals
| Market cap | $474.17M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 69.02M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 12.91 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.60 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 17.13 |
| Quick ratio | N/A |